{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:31:57Z","timestamp":1776285117872,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003638","name":"Korea Health Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003638","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003991","name":"Ministry of Health & Welfare, Republic of Korea","doi-asserted-by":"publisher","award":["HI14C2202"],"award-info":[{"award-number":["HI14C2202"]}],"id":[{"id":"10.13039\/501100003991","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003991","name":"Ministry of Health & Welfare, Republic of Korea","doi-asserted-by":"publisher","award":["HI15C0001"],"award-info":[{"award-number":["HI15C0001"]}],"id":[{"id":"10.13039\/501100003991","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.phrs.2015.06.008","type":"journal-article","created":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T03:19:38Z","timestamp":1435202378000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Novel insight into drug repositioning: Methylthiouracil as a case in point"],"prefix":"10.1016","volume":"99","author":[{"given":"Moon-Chang","family":"Baek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeongjin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyejin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Shik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Sup","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2015.06.008_bib0535","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/0022-3859.81870","article-title":"Drug repositioning: re-investigating existing drugs for new therapeutic indications","volume":"57","author":"Padhy","year":"2011","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.phrs.2015.06.008_bib0540","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","article-title":"Shifting from the single to the multitarget paradigm in drug discovery","volume":"18","author":"Medina-Franco","year":"2013","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.phrs.2015.06.008_bib0545","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/icc\/dtp035","article-title":"Academic collaboration and organizational innovation: the development of research capabilities in the US pharmaceutical industry, 1927\u20131946*","volume":"18","author":"Furman","year":"2009","journal-title":"Ind Corp Change"},{"key":"10.1016\/j.phrs.2015.06.008_bib0550","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1021\/ar800257v","article-title":"Chemical process research and development in the 21st century: challenges, strategies, and solutions from a pharmaceutical industry perspective","volume":"42","author":"Federsel","year":"2009","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.phrs.2015.06.008_bib0555","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.drudis.2009.09.007","article-title":"Drug discovery dilemma and cura quartet collaboration","volume":"14","author":"Shah","year":"2009","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.phrs.2015.06.008_bib0560","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2961","article-title":"Lessons from 60 years of pharmaceutical innovation","volume":"8","author":"Munos","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.phrs.2015.06.008_bib0565","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrd898","article-title":"Erectile-dysfunction therapies","volume":"1","author":"Renaud","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.phrs.2015.06.008_bib0570","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01806132","article-title":"Effects of anti-estrogens on bone in castrated and intact female rats","volume":"10","author":"Jordan","year":"1987","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.phrs.2015.06.008_bib0575","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2337\/db12-1530","article-title":"Teaching an old drug new tricks: can paroxetine ease the burden of cardiovascular disease in diabetes","volume":"62","author":"Wheatcroft","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2015.06.008_bib0580","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.phrs.2015.06.008_bib0585","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2174\/0929867311320130005","article-title":"Predicting targeted polypharmacology for drug repositioning and multi-target drug discovery","volume":"20","author":"Liu","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.phrs.2015.06.008_bib0590","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/clpt.2009.293","article-title":"Deconstructing the drug development process: the new face of innovation","volume":"87","author":"Kaitin","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2015.06.008_bib0595","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1358\/dnp.2009.22.2.1343228","article-title":"The value of drug repositioning in the current pharmaceutical market","volume":"22","author":"Tobinick","year":"2009","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.phrs.2015.06.008_bib0600","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nrd1900","article-title":"Finding new tricks for old drugs: an efficient route for public-sector drug discovery","volume":"4","author":"O\u2019Connor","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.phrs.2015.06.008_bib0605","first-page":"10","article-title":"Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis","author":"Vesterinen","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.phrs.2015.06.008_bib0610","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/ph6101304","article-title":"Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease","volume":"6","author":"Corbett","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.phrs.2015.06.008_bib0615","series-title":"Pharmaceutical product relaunch: preserving market share through line extension and new market entry strategies","author":"Cutting edge information","year":"2007"},{"key":"10.1016\/j.phrs.2015.06.008_bib0620","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","article-title":"Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the quality standards subcommittee of the American Academy of Neurology","volume":"58","author":"Miyasaki","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2015.06.008_bib0625","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1212\/WNL.64.12_suppl_3.S28","article-title":"New paradigms in the treatment of restless legs syndrome","volume":"64","author":"Thorpy","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2015.06.008_bib0630","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/2229-3485.71852","article-title":"Phase iv of drug development","volume":"1","author":"Suvarna","year":"2010","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.phrs.2015.06.008_bib0635","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1592\/phco.26.3.323","article-title":"The major role of clinicians in the discovery of off-label drug therapies","volume":"26","author":"Demonaco","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2015.06.008_bib0640","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2174\/156802612801784407","article-title":"Thalidomide chemistry, therapeutic potential and oxidative stress induced teratogenicity","volume":"12","author":"Kumar","year":"2012","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.phrs.2015.06.008_bib0645","first-page":"271","article-title":"Dark remedy: the impact of thalidomide and its revival as a vital medicine","volume":"14","author":"Lusk","year":"2006","journal-title":"Nurs Hist Rev"},{"key":"10.1016\/j.phrs.2015.06.008_bib0650","first-page":"8","article-title":"Eortc-nci-aacr \u2013 18th symposium \u2013 molecular targets and cancer therapeutics. New approaches in treating cancer","volume":"10","author":"Murch","year":"2007","journal-title":"IDrugs"},{"key":"10.1016\/j.phrs.2015.06.008_bib0655","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nchembio840","article-title":"New approaches to molecular cancer therapeutics","volume":"2","author":"Collins","year":"2006","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0660","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/msj.20197","article-title":"Integration of small-molecule discovery in academic biomedical research","volume":"77","author":"Ohlmeyer","year":"2010","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.phrs.2015.06.008_bib0665","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1091867","article-title":"Medicine. The NIH roadmap","volume":"302","author":"Zerhouni","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.phrs.2015.06.008_bib0670","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nm0110-7b","article-title":"Matchmaking service links up researchers to wallflower drugs","volume":"16","author":"Schubert","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.phrs.2015.06.008_bib0675","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ddstr.2011.06.006","article-title":"The ctsa pharmaceutical assets portal \u2013 a public\u2013private partnership model for drug repositioning","volume":"8","author":"Marusina","year":"2011","journal-title":"Drug Discov Today Ther Strateg"},{"key":"10.1016\/j.phrs.2015.06.008_bib0680","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","article-title":"Drug repurposing: far beyond new targets for old drugs","volume":"14","author":"Oprea","year":"2012","journal-title":"AAPS J"},{"key":"10.1016\/j.phrs.2015.06.008_bib0685","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/17512433.2014.884923","article-title":"Repackaging fda-approved drugs for degenerative diseases: promises and challenges","volume":"7","author":"Cummings","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0690","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1126\/science.1235857","article-title":"Drug patents at the Supreme Court","volume":"339","author":"Hemphill","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.phrs.2015.06.008_bib0695","first-page":"6","article-title":"Use patents can be useful: the case of rescued drugs","author":"Rai","year":"2014","journal-title":"Sci Trans Med"},{"key":"10.1016\/j.phrs.2015.06.008_bib0700","doi-asserted-by":"crossref","first-page":"e115460","DOI":"10.1371\/journal.pone.0115460","article-title":"The application of the open pharmacological concepts triple store (open phacts) to support drug discovery research","volume":"9","author":"Ratnam","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.phrs.2015.06.008_bib0705","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0528.1989.tb00623.x","article-title":"Periodontal conditions in adults with rheumatoid arthritis","volume":"17","author":"Sjostrom","year":"1989","journal-title":"Community Dent Oral Epidemiol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0710","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1600-051X.1990.tb01091.x","article-title":"Serum antibodies and loss of periodontal bone in patients with rheumatoid arthritis","volume":"17","author":"Tolo","year":"1990","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0715","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1902\/jop.2001.72.6.779","article-title":"Relationship between rheumatoid arthritis and periodontitis","volume":"72","author":"Mercado","year":"2001","journal-title":"J Periodontol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0720","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1034\/j.1600-051x.2000.027004267.x","article-title":"Is there a relationship between rheumatoid arthritis and periodontal disease","volume":"27","author":"Mercado","year":"2000","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0725","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/art.1780401221","article-title":"Risk for periodontal disease in patients with longstanding rheumatoid arthritis","volume":"40","author":"Kasser","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2015.06.008_bib0730","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1902\/jop.2005.76.2.229","article-title":"Experimental arthritis in rats induces biomarkers of periodontitis which are ameliorated by gene therapy with tissue inhibitor of matrix metalloproteinases","volume":"76","author":"Ramamurthy","year":"2005","journal-title":"J Periodontol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0735","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.1780390502","article-title":"Guidelines for monitoring drug therapy in rheumatoid arthritis","volume":"39","author":"Guidelines ACoRAHCoC","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2015.06.008_bib0740","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.1780390503","article-title":"Guidelines for monitoring drug therapy in rheumatoid arthritis","volume":"39","author":"Guidelines ACoRAHCoC","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2015.06.008_bib0745","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/odi.12159","article-title":"Matrix metalloproteinases and periodontal diseases","volume":"20","author":"Sapna","year":"2014","journal-title":"Oral Dis"},{"key":"10.1016\/j.phrs.2015.06.008_bib0750","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1600-0765.1983.tb00388.x","article-title":"Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action","volume":"18","author":"Golub","year":"1983","journal-title":"J Periodontal Res"},{"key":"10.1016\/j.phrs.2015.06.008_bib0755","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/00220345870660080401","article-title":"A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity","volume":"66","author":"Golub","year":"1987","journal-title":"J Dent Res"},{"key":"10.1016\/j.phrs.2015.06.008_bib0760","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1902\/annals.2003.8.1.12","article-title":"Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review","volume":"8","author":"Reddy","year":"2003","journal-title":"Ann Periodontol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0765","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1902\/jop.2004.75.8.1068","article-title":"Subantimicrobial dose doxycycline enhances the efficacy of scaling and root planning in chronic periodontitis: a multicenter trial","volume":"75","author":"Preshaw","year":"2004","journal-title":"J Periodontol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0770","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-122-2-199501150-00001","article-title":"Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. Mira trial group","volume":"122","author":"Tilley","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.phrs.2015.06.008_bib0775","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1345\/aph.1E282","article-title":"Use of macrolides and tetracyclines for chronic inflammatory diseases","volume":"39","author":"Voils","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.phrs.2015.06.008_bib0780","article-title":"Treatment of early sero-positive rheumatoid arthritis: doxycycline with methotrexate versus methotrexate alone","volume":"48","author":"Elliott","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2015.06.008_bib0785","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00002281-199605000-00013","article-title":"Potential of tetracyclines to modify cartilage breakdown in osteoarthritis","volume":"8","author":"Ryan","year":"1996","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0790","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7","article-title":"Specificity of inhibition of matrix metalloproteinase activity by doxycycline: Relationship to structure of the enzyme","volume":"42","author":"Smith","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2015.06.008_bib0795","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/1529-0131(199907)42:7<1517::AID-ANR27>3.0.CO;2-G","article-title":"Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis","volume":"42","author":"Westhoff","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2015.06.008_bib0800","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/ard.2003.013243","article-title":"Mmp profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis","volume":"63","author":"Tchetverikov","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.phrs.2015.06.008_bib0805","doi-asserted-by":"crossref","first-page":"14014","DOI":"10.1073\/pnas.93.24.14014","article-title":"A novel mechanism of action of tetracyclines: effects on nitric oxide synthases","volume":"93","author":"Amin","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2015.06.008_bib0810","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1006\/bbrc.1999.0929","article-title":"Doxycycline induces fas\/fas ligand-mediated apoptosis in jurkat t lymphocytes","volume":"260","author":"Liu","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2015.06.008_bib0815","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1128\/AAC.47.11.3630-3633.2003","article-title":"Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines","volume":"47","author":"Krakauer","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.phrs.2015.06.008_bib0820","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/art.21620","article-title":"Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone","volume":"54","author":"O\u2019Dell","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2015.06.008_bib0825","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.phrs.2015.06.008_bib0830","series-title":"Properties of organic compounds. CRC Press database","author":"Lide","year":"1996"},{"key":"10.1016\/j.phrs.2015.06.008_bib0835","unstructured":"Medical products agency. Uppsala, 2000."},{"key":"10.1016\/j.phrs.2015.06.008_bib0840","unstructured":"Medicines control agency. London, 2000."},{"key":"10.1016\/j.phrs.2015.06.008_bib0845","unstructured":"Medicines evaluation board agency. The Hague, 2000."},{"key":"10.1016\/j.phrs.2015.06.008_bib0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1388-1981(00)00105-0","article-title":"The expanding superfamily of phospholipase a(2) enzymes: classification and characterization","volume":"1488","author":"Six","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.phrs.2015.06.008_bib0855","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0090-6980(02)00020-5","article-title":"Phospholipase a2 enzymes","volume":"68\/69","author":"Kudo","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.phrs.2015.06.008_bib0860","doi-asserted-by":"crossref","first-page":"14411","DOI":"10.1074\/jbc.273.23.14411","article-title":"The functions of five distinct mammalian phospholipase a2s in regulating arachidonic acid release. Type iia and type v secretory phospholipase a2s are functionally redundant and act in concert with cytosolic phospholipase a2","volume":"273","author":"Murakami","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2015.06.008_bib0865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prostaglandins.2005.10.005","article-title":"Secretory phospholipase a2 of group iia: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases","volume":"79","author":"Menschikowski","year":"2006","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.phrs.2015.06.008_bib0870","doi-asserted-by":"crossref","first-page":"23764","DOI":"10.1074\/jbc.273.37.23764","article-title":"Inhibition of prothrombinase by human secretory phospholipase a2 involves binding to factor xa","volume":"273","author":"Mounier","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2015.06.008_bib0875","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1172\/JCI117022","article-title":"Lipopolysaccharide (lps)-binding protein and soluble cd14 function as accessory molecules for lps-induced changes in endothelial barrier function, in vitro","volume":"93","author":"Goldblum","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2015.06.008_bib0880","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1056\/NEJMra043632","article-title":"Management of sepsis","volume":"355","author":"Russell","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2015.06.008_bib0885","first-page":"2954","article-title":"Tnf-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice","volume":"119","author":"Baluk","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2015.06.008_bib0890","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1152\/physrev.00012.2005","article-title":"Signaling mechanisms regulating endothelial permeability","volume":"86","author":"Mehta","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.phrs.2015.06.008_bib0895","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/mol.61.4.786","article-title":"Arachidonic acid differentially affects basal and lipopolysaccharide-induced spla(2)-iia expression in alveolar macrophages through nf-kappab and ppar-gamma-dependent pathways","volume":"61","author":"Alaoui-El-Azher","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0900","doi-asserted-by":"crossref","first-page":"20124","DOI":"10.1074\/jbc.M611883200","article-title":"A novel role of group vib calcium-independent phospholipase a2 (ipla2gamma) in the inducible expression of group iia secretory pla2 in rat fibroblastic cells","volume":"282","author":"Kuwata","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2015.06.008_bib0905","first-page":"433","article-title":"Lipopolysaccharide induces time-dependent increases in prostaglandin h synthase-2 and cytosolic phospholipase a2 MRNA in cultured human microvessel-derived endothelial cells","volume":"4","author":"Flynn","year":"1995","journal-title":"Shock"},{"key":"10.1016\/j.phrs.2015.06.008_bib0910","doi-asserted-by":"crossref","first-page":"9956","DOI":"10.1016\/S0021-9258(18)92912-1","article-title":"Inflammatory factors stimulate expression of group ii phospholipase a2 in rat cultured astrocytes. Two distinct pathways of the gene expression","volume":"266","author":"Oka","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2015.06.008_bib0915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0968-0004(96)20031-3","article-title":"The growing phospholipase a2 superfamily of signal transduction enzymes","volume":"22","author":"Dennis","year":"1997","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.phrs.2015.06.008_bib0920","first-page":"143","article-title":"Phospholipase a2 \u2013 a mediator between proximal and distal effectors of inflammation","volume":"12","author":"Pruzanski","year":"1991","journal-title":"Immunol Today"},{"key":"10.1016\/j.phrs.2015.06.008_bib0925","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF01711354","article-title":"Prognostic value of serum phospholipase a in the multitraumatized patient","volume":"67","author":"Waydhas","year":"1989","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.phrs.2015.06.008_bib0930","doi-asserted-by":"crossref","first-page":"12745","DOI":"10.1016\/S0021-9258(19)38408-X","article-title":"Glucocorticoids suppress group ii phospholipase a2 production by blocking MRNA synthesis and post-transcriptional expression","volume":"265","author":"Nakano","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2015.06.008_bib0935","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1016\/S0021-9258(18)52293-6","article-title":"Induction of phospholipase a2 gene expression in human hepatoma cells by mediators of the acute phase response","volume":"266","author":"Crowl","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2015.06.008_bib0940","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/jnnp.40.10.967","article-title":"Measurement of prostaglandin e2 in cerebrospinal fluid in patients suffering from stroke","volume":"40","author":"Carasso","year":"1977","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.phrs.2015.06.008_bib0945","first-page":"145","article-title":"Prostaglandin d2 produced by hematopoietic prostaglandin d synthase contributes to lps-induced fever","volume":"60","author":"Gao","year":"2009","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0950","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/37635","article-title":"Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase a2","volume":"390","author":"Bonventre","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2015.06.008_bib0955","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1074\/jbc.M707345200","article-title":"Mechanism of regulation of group iva phospholipase a2 activity by ser727 phosphorylation","volume":"283","author":"Tian","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2015.06.008_bib0960","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF02570682","article-title":"Thyroid carcinogenesis in hamsters after treatment with 131-iodine and methylthiouracil","volume":"77","author":"Christov","year":"1972","journal-title":"Z Krebsforsch Klin Onkol Cancer Res Clin Oncol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0965","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1677\/joe.0.0450483","article-title":"Development of goitre after methylthiouracil treatment of mice with hypothalamic lesions","volume":"45","author":"Moll","year":"1969","journal-title":"J Endocrinol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0970","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00408100","article-title":"On the development of metastasizing tumors of the rat thyroid gland after combined administration of nitrosomethylurea and methylthiouracil","volume":"96","author":"Schaffer","year":"1980","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0975","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd1854","article-title":"Animal models of sepsis: setting the stage","volume":"4","author":"Buras","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.phrs.2015.06.008_bib0980","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jat.727","article-title":"A good practice guide to the administration of substances and removal of blood, including routes and volumes","volume":"21","author":"Diehl","year":"2001","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.phrs.2015.06.008_bib0985","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/S0140-6736(98)01134-9","article-title":"Septic shock","volume":"351","author":"Astiz","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2015.06.008_bib0990","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1172\/JCI118664","article-title":"Expression of human group ii pla2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate","volume":"97","author":"Grass","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2015.06.008_bib0995","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0006-291X(02)02920-0","article-title":"Secreted phospholipases a2 induce the expression of chemokines in microvascular endothelium","volume":"300","author":"Beck","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2015.06.008_bib1000","first-page":"161","article-title":"Side effects of single and combined administration of methylthiouracil, p-hydroxypropiophenone, diiodothyrosine and alloxan on the blood cell count, hemoglobin content and blood sugar level in albino rats","volume":"47","author":"Scharf","year":"1965","journal-title":"Endokrinologie"},{"key":"10.1016\/j.phrs.2015.06.008_bib1005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1089\/thy.2009.0169","article-title":"The role of propylthiouracil in the management of Graves\u2019 disease in adults: Report of a meeting jointly sponsored by the American thyroid association and the food and drug administration","volume":"19","author":"Bahn","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.phrs.2015.06.008_bib1010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1089\/wound.2012.0422","article-title":"Translational bioinformatics approaches to drug development","volume":"2","author":"Readhead","year":"2013","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"10.1016\/j.phrs.2015.06.008_bib1015","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2015.06.008_bib1020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nrd1766","article-title":"Why big pharma needs to learn the three \u2018r's","volume":"4","author":"Bradley","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.phrs.2015.06.008_bib1025","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1169920","article-title":"Drug discovery. Repurposing with a difference","volume":"324","author":"Boguski","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.phrs.2015.06.008_bib1030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000345791","article-title":"A review: treatment of Alzheimer's disease discovered in repurposed agents","volume":"35","author":"Appleby","year":"2013","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.phrs.2015.06.008_bib1035","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","article-title":"Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines","volume":"19","author":"Jin","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.phrs.2015.06.008_bib1040","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1164\/rccm.201311-2033OC","article-title":"Transforming growth factor beta-induced protein promotes severe vascular inflammatory responses","volume":"189","author":"Bae","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.phrs.2015.06.008_bib1045","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5483\/BMBRep.2014.47.6.198","article-title":"Inhibitory effects of oroxylin a on endothelial protein c receptor shedding in vitro and in vivo","volume":"47","author":"Ku","year":"2014","journal-title":"BMB Rep"},{"key":"10.1016\/j.phrs.2015.06.008_bib1050","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s12272-014-0403-8","article-title":"Antithrombotic activities of sulforaphane via inhibiting platelet aggregation and fiia\/fxa","volume":"37","author":"Ku","year":"2014","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.phrs.2015.06.008_bib1055","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.thromres.2009.07.015","article-title":"Thrombin and activated protein c inhibit the expression of secretory group iia phospholipase a(2) in the tnf-alpha-activated endothelial cells by epcr and par-1 dependent mechanisms","volume":"125","author":"Bae","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.phrs.2015.06.008_bib1060","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1248\/bpb.24.1004","article-title":"Characterization of secretory type iia phospholipase a2 (spla2-iia) as a glycyrrhizin (gl)-binding protein and the gl-induced inhibition of the ck-ii-mediated stimulation of spla2-iia activity in vitro","volume":"24","author":"Shimoyama","year":"2001","journal-title":"Biol Pharm Bull"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181500122X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181500122X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T18:01:56Z","timestamp":1717956116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366181500122X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":106,"alternative-id":["S104366181500122X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2015.06.008","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel insight into drug repositioning: Methylthiouracil as a case in point","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2015.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}